These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19232014)

  • 41. A case hypersensitive to bimatoprost and dexamethasone.
    Li X; Liu G; Wang Y; Yu W; Xiang H; Liu X
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):519-23. PubMed ID: 21936632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
    Ranno S; Sacchi M; Brancato C; Gilardi D; Lembo A; Nucci P
    ScientificWorldJournal; 2012; 2012():804730. PubMed ID: 22606063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostaglandin agonist effect on matrix metalloproteinase aqueous levels in glaucoma patients.
    Pradhan ZS; Dalvi RA; Lai T; Kranemann C; Boyd S; Birt CM
    Can J Ophthalmol; 2015 Feb; 50(1):6-10. PubMed ID: 25677276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence.
    Zimmerman TJ; Hahn SR; Gelb L; Tan H; Kim EE
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):145-52. PubMed ID: 19284321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit.
    Chen W; Dong N; Huang C; Zhang Z; Hu J; Xie H; Pan J; Liu Z
    PLoS One; 2014; 9(3):e89205. PubMed ID: 24632558
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
    Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
    Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops.
    Kozobolis VP; Detorakis ET; Maskaleris G; Koukoula SC; Fountoulakis N; Chrysochoou F; Konstas AG
    Am J Ophthalmol; 2005 Apr; 139(4):742-3. PubMed ID: 15808188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Bimatoprost in the treatment of ocular hypertension and chronic glaucoma].
    Detry-Morel M
    J Fr Ophtalmol; 2005 Mar; 28(3):285-9. PubMed ID: 15883493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2005 Nov; 21(11):1875-83. PubMed ID: 16307709
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of prostaglandin analogues on central corneal thickness in patients with glaucoma: A systematic review and meta-analysis with trial sequential analysis.
    Kadri R; Shetty A; Parameshwar D; Kudva AA; Achar A; Shetty J
    Indian J Ophthalmol; 2022 May; 70(5):1502-1512. PubMed ID: 35502015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension.
    Hepsen IF; Ozkaya E
    Eye (Lond); 2007 Apr; 21(4):453-8. PubMed ID: 16543930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients.
    Martinez A; Sanchez M
    Eye (Lond); 2009 Apr; 23(4):810-8. PubMed ID: 18535605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bimatoprost versus travoprost in an Egyptian population: a hospital-based prospective, randomized study.
    Macky TA
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):605-10. PubMed ID: 21034177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.
    Kucukevcilioglu M; Bayer A; Uysal Y; Altinsoy HI
    Clin Exp Ophthalmol; 2014 Mar; 42(2):126-31. PubMed ID: 23844550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol.
    Mesci C; Aydin N; Erbil HH
    J Glaucoma; 2011 Oct; 20(8):477-81. PubMed ID: 21048508
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
    Sharif NA; Kelly CR; Crider JY; Williams GW; Xu SX
    J Ocul Pharmacol Ther; 2003 Dec; 19(6):501-15. PubMed ID: 14733708
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
    Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.